A randomized trial was launched in Côte d'Ivoire in 2002 to compare continuous antiretroviral treatment (hereafter, "C-ART") to an ART regimen of 2 months off and 4 months on therapy (hereafter, "2/4 -ART"). We report the final analysis.
Scheduled treatment interruptions (STIs) of antiretroviral treatment (ART) in chronically HIV-infected patients have been studied in various randomized trials [1] [2] [3] [4] . The main objective of these trials was to assess whether a given STI strategy could reduce antiretroviral drug toxicity and cost for successfully treated patients while maintaining clinical and immunological efficacy comparable to that observed in patients receiving continuous treatment.
Among the STI strategies that were assessed, some were guided by changes in patients' CD4 cell counts, with interruptions of and reintroductions to ART occurring at predefined CD4 cell count thresholds [5] [6] [7] [8] [9] [10] [11] . Other STI strategies, referred to as "fixed" strategies, alternated ART interruptions and reintroductions in accordance with a schedule of predefined periods [12] [13] [14] [15] [16] [17] . Some trials have demonstrated significantly higher risks of drug resistance, virological failure, or clinical progression due to STI [8, 10, 13, 14, 17, 18] , although others have shown that the trial strategy was not significantly different than-or was noninferior to-continuous ART [5, 11, 12, 18] .
As a result of these trials, there are currently no STI strategies recommended, even though STI was shown to be noninferior to continuous ART in some cases. STI strategies have been treated with caution for 2 reasons. First, even the trials that reached favorable conclusions with respect to clinical and immunological outcomes failed to demonstrate major advantages in secondary outcomes [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Second, the trial with the greatest statistical power demonstrated troubling non-HIV-related morbidity outcomes, suggesting that STIs may significantly increase the risks of nonopportunistic diseases across all CD4 cell-count strata, contrary to expectations at the beginning of the STI trials era [8, 19] .
Most trials reporting negative outcomes for STIs used strategies guided by CD4 cell count [8, 20] or fixed strategies with relatively short treatment periods [13, 17] . Fixed strategies that stipulate longer times "on" ART and shorter times "off" ART may ensure plasma viral load resuppression at each cycle and limit the chance of uncontrolled viral replication. In 2002, we launched a randomized trial in Cote d'Ivoire to compare continuous ART (hereafter, "C-ART") with 2 STI strategies, a CD4 cell count-guided sART trategy and a fixed 2-months-off, 4-months-on ART strategy (hereafter, "2/4 -ART"). The CD4-guided strategy was prematurely interrupted [20] . The 2/4 -ART and C-ART strategies were continued until trial termination. We report here the results of the final analysis comparing these 2 strategies.
METHODS
The study protocol was approved by the ethics committees of the Ministry of Health of Côte d'Ivoire and by the institutional review board of the French National Agency for Research on AIDS (ANRS). This study is registered at ClinicalTrials.gov (trial NCT00158405). All participants gave written informed consent.
Settings and eligibility. The study methods have been described elsewhere [20] . Between December 2002 and April 2004, all HIV-infected adults followed up in 5 HIV infection clinics were candidates for inclusion if they had either a CD4 cell count of 150 -350 cells/mm 3 or a CD4 cell percentage of 12.5%-20%. They were not included if any of the following factors were present: age Ͻ18 years; a history of ART, excluding time-limited ART aimed at preventing mother-to-child transmission of HIV; pregnancy; severe renal, hepatic or hematological disorder; residence outside of Abidjan; Karnofsky score Ͻ50; and/or severe psychiatric disease.
Intervention. The trial comprised 2 phases. In the prerandomization phase, all patients received continuous ART. The first-line regimen was zidovudine and lamivudine (Duovir; Cipla), combined with 1 of the following: efavirenz, 600 mg once a day (Stocrin; Merck Sharp & Dohme), or indinavir-ritonavir, 800 and 100 mg twice a day, respectively (Crixivan, Merck Sharp & Dohme; Norvir, Abbott), for HIV-2 infected patients, women who refused contraception, and women with a past history of treatment with single-dose nevirapine. Once patients were included in the trial, drug substitutions were allowed in cases of intolerance or treatment failure.
Patients were randomized into 1 of 3 study arms after 6 -18 months in the prerandomization phase if they met all of the following randomization criteria: CD4 cell count Ͼ350 cells/ mm 3 , plasma HIV-1 RNA level Ͻ300 copies/mL, absence of ongoing morbidity episode or pregnancy, ongoing ART regimen excluding abacavir and nevirapine, and no history of ART regimen modification during the prerandomization phase. Abacavir and nevirapine were not allowed because of the risk of hypersensitivity at each drug reintroduction. The 3 study arms were as follows: (1) a C-ART arm, (2) a CD4 cell count-guided therapy arm, and (3) a 2/4 -ART arm.
Objectives. The trial aimed to test the hypothesis that each episodic arm was noninferior to the continuous treatment arm.
End points. Three primary end points were defined a priori: (1) mortality; (2) incidence of severe morbidity, combining any event leading to death and any event that was classified as a World Health Organization clinical stage 3 or 4 event; and (3) the percentage of patients with a CD4 cell count Ͻ350 cells/mm 3 at 24 months. Severe morbidity and mortality were a priori hypothesized to be rare and were not used for sample size calculation.
Secondary end points were viral and immunological efficacy, adherence, percentage of patients with virus resistant to 1 drug at 24 months, cost of care, and incidence of ANRS grade 3 or 4 adverse events [21] . All reports of potential clinical outcomes were referred to an event documentation committee for independent review.
Randomization. A computer-generated, sequentially-numbered, blocked randomization list, stratified by trial center, was drawn up by an independent statistician and then incorporated into a software program that provided access to the next available number. Before physicians could randomize patients, the trial coordinator in Abidjan first verified that randomization criteria had been met and then assigned the next available number to the patient. Neither participants nor trial teams were blinded to the intervention.
Follow-up. Patients were asked to return to their study clinic every month and had access to it at any point during the interval. Standardized questionnaires were used to record characteristics at baseline and at each monthly visit. Symptoms were managed in accordance with standardized algorithms. Transportation, consultations, investigations, hospitalizations, and drugs were free of charge, regardless of whether patients stayed in the study or dropped out. The Côte d'Ivoire Ministry of Health committed to financing treatment for all participants after study completion.
CD4 cell count (obtained with the True Count technique; FACScan, Becton Dickinson) was measured every 2 months. Plasma HIV-1 RNA level was measured every 6 months (by use of real-time polymerase chain reaction and Taq Man technology [lower limit of detectability, 300 copies/mL]; Abi Prism 7000, Applied Biosystems) [22] . HIV-1 genotypic drug-resistance tests were performed by sequencing reverse-transcriptase (RT) and protease genes for all viral loads 300 copies/mL on frozen plasma samples collected at month 12 and month 24 from patients in the C-ART and the 2/4 -ART arms [23] . Resistance mutations were defined according to the International AIDS Society-USA 2007 list [24] . Drug resistance was defined according to the 2007 French ANRS algorithm [25] . Serum levels of liver enzymes and creatinine were measured every 2 months; levels of glucose, cholesterol, and triglycerides were measured every 12 months. Home visits were arranged for all patients who did not attend scheduled appointments. Patients from the episodic arms were prescribed a continuous treatment with no further interruptions at the first severe morbidity event, pregnancy, or decrease of CD4 cell count below 200 cells/mm 3 .
Drugs. Cotrimoxazole prophylaxis was given irrespective of CD4 cell count, except when patients had a history of severe intolerance to the drug. Every month, the trial center pharmacies provided patients who were receiving ART with the quantity of antiretroviral pills required for 35 days. Patients who were not receiving treatment were instructed not to take any antiretroviral drug during the following month. Patients who interrupted an efavirenz-based treatment regimen were instructed to stop the 2 nucleoside reverse-transcriptase inhibitors (NRTIs) 5 days later than efavirenz.
Sample size. Final noninferiority analyses were planned to compare each episodic arm and the C-ART arm separately, by using both the intent-to-treat and per-protocol approaches. Each episodic strategy would be considered noninferior to the C-ART strategy if the lower bound of the 95% confidence interval (LBCI) for the difference in event rate between the C-ART arm and the episodic arm was lower than the noninferiority bound (NIB). The NIB was Ϫ5/100 person-years for mortality, Ϫ15/100 person-years for morbidity, and Ϫ15% for CD4 cell count at 24 months.
The number of patients in the CD4 cell count-guided and 2/4 -ART arms was 2 and 3 times higher than in the C-ART arm, respectively. This decision was made a priori, on the basis of an expected higher variability in outcomes for both episodic arms.
The sample size calculation was based on the third primary outcome (CD4 cell count) and on the intent-to-treat approach. The main hypothesis was that 30% of the patients in the C-ART arm would have a CD4 cell count Ͻ350 cells/mm 3 at month 24. The null hypothesis was that the percentage of patients with Ͻ350 CD4 cells/mm 3 at month 24 would be at least 15% higher in the 2/4 -ART arm. The calculated sample size of 105 patients randomized to the C-ART arm, 210 randomized to the CD4 cell count-guided arm, and 315 to the 2/4 -ART arm ensured an 80% power to demonstrate noninferiority by using a 1-sided 95% confidence interval. Assuming that 70% of patients would meet the randomization criteria and that 5% of the patients could be lost to follow-up, the total sample size was calculated at 840. This sample size ensured an 80% power to demonstrate noninferiority for mortality and morbidity, assuming a mortality rate of 0.3 deaths/100 person-years and a morbidity rate of 3.7 events/100 person-years in the C-ART arm.
Statistical analysis. In October 2006, the data safety management board recommended that the CD4 cell count-guided arm of the study be stopped because of a high severe morbidity rate [20] . The 2/4 -ART and C-ART arms were continued until the scheduled trial termination date (i.e., last patient reaching 24 months of follow-up).
Here, we present the final results as of March 24, 2007 , when all follow-up data was finalized. Patients were defined as lost to follow-up if their last contact with the study team occurred before the date scheduled for their 24-month visit, they were not known to be dead, and no further information on their vital status was available on September 30, 2007. For the end point of CD4 cell count Ͻ350 cells/mm 3 at month 24, all patients were eligible for the intent-to-treat analysis; the per-protocol analysis was restricted to patients remaining in the trial strategy. For mortality and morbidity rate, all patients were eligible for intent-to-treat and per-protocol analysis. In the perprotocol analysis, the follow-up data was censored at the time of withdrawal from the strategy for patients in the 2/4 -ART arm who were prescribed C-ART with no further interruption.
For the main outcomes, the 95% confidence interval for the difference between arms was difference Ϯ z ␣/ 2 ϫ SE for the difference. For mortality and morbidity per 100 person-years, the SE was ͙(a/N 1 2 ϩb/N 0 2 ), where a was the number of first events in the C-ART arm, b was the number of first events in the 2/4 -ART arm, N 1 was person-time in the C-ART arm, and N 0 was persontime in the 2/4 -ART arm. For the percentage of patients with CD4 cell count Ͻ350 cells/mm 3 at 24 months, the SE was ͌[Var(percentage in the C-ART arm) ϩ Var(percentage in the 2/4 -ART arm)].
Secondary end points were compared by using superiority analysis. For time-dependent secondary end points (grade 3-4 toxicity and non-HIV-related morbidity), study arms were compared by using time-to-first-event analyses, including KaplanMeier estimates and log-rank testing. For percentages at month 24 (detectable viral load, drug resistance, high blood pressure, and lipodystrophy), comparisons between study arms were done by using 2 tests or Fisher's exact tests. For adherence, the percentage of patients self-reporting 1 pill missed at any visit was compared by using a random effect logistic regression model [26] . The cost of care was calculated for each individual by adding up the cost of drugs actually given, clinic visits actually attended, hospitalizations, and biological tests performed during follow-up in the trial. We compared the distribution of cost per year of follow-up by using the Kruskal-Wallis test.
The reported P values are not adjusted for multiple testing. Analyses were performed with SAS software (version 9.1; SAS Institute). Figure 1 shows the disposition of participants through each stage. Of the 840 patients originally included, 651 were randomized into the trial (110 in the C-ART arm, 325 in the 2/4 -ART arm, and 216 in the CD4 cell count-guided arm) and 189 were never randomized. The reasons for not being randomized were death before 18 months in the prerandomization phase (n ϭ 21), loss to follow-up before 18 months in the prerandomization phase (n ϭ 23), randomization closed (n ϭ 3), and absence of 1 randomization criteria at month 18 in the prerandomization phase (n ϭ 145). The latter group included patients with CD4 cell count Ͻ350 cells/mm 3 (n ϭ 115), detectable viral load at last measurement (n ϭ 34), ongoing severe HIV disease (n ϭ 19), ART regimen modification during the prerandomization phase (n ϭ 7), pregnancy (n ϭ 2), and ART regimen including abacavir or nevirapine (n ϭ 6). Table 1 shows the demographic and clinical characteristics of the 435 patients randomized into the C-ART and 2/4 -ART arms. The loss to follow-up incidence was 1.08 losses/100 person-years in the 2/4 -ART arm and 0.9 losses/100 personyears in the C-ART arm (incidence rate ratio, 1.19 [95% CI, 0.23-11.79]; P ϭ .88). the LBCI (Ϫ13.9 %) was close to the NIB (Ϫ15%). Mortality was low in both arms (0.46 and 0.45 deaths/100 person-years), and the LBCI for the difference between arms (Ϫ0.87%) was very far from the NIB (Ϫ5%). The rate of severe morbidity was intermediate in both arms (9.2 and 6.8 events/100 person-years) and the LBCI (Ϫ5.9 %) was far from the NIB (Ϫ15%). The most fre- NOTE. ART, antiretroviral treatment; BMI, body mass index; C-ART, continuous antiretroviral treatment; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, Protease inhibitor; 2/4 -ART, 2-months-off, 4-months-on antiretroviral treatment; ULN, upper limit of normal; VL, viral load; WHO, World Health Organization.
RESULTS

Participants and follow-up.
a Data were missing for 3 individuals. b Including zidovudine (ZDV)-lamivudine (3TC)-indinavir-ritonavir (n ϭ 37), ZDV-3TC-lopinavir-ritonavir (n ϭ 3), ZDV-3TC-nelfinavir (n ϭ 2), and stavudine-3TC-indinavir-ritonavir (n ϭ 1).
c Including ZDV-3TC-efavirenz (n ϭ 378), stavudine-3TC-efavirenz (n ϭ 12), and didanosine-3TC-efavirenz (n ϭ 1). quent stage 3 or 4 morbidity events observed in both arms were oropharyngeal candidiasis (n ϭ 46), invasive bacterial diseases (n ϭ 26), tuberculosis (n ϭ 15), unexplained syndrome leading to death (n ϭ 4), esophageal candidiasis (n ϭ 2), and isosporosis (n ϭ 1). Figure 2 shows the CD4 cell count evolution in both arms by intent-to-treat.
Secondary outcomes. Table 3 shows the results of the superiority analyses on the secondary outcomes. Of the 435 patients randomized, 422 (97%) (315 in the 2/4 -ART arm and 107 in the C-ART arm) had a viral load measurement available at 24 months. Among them, 86 had virus resistant to 1 drugs (76 [24%] in the 2/4 -ART arm and 10 [9%] in the C-ART arm; P ϭ .001), including 60 patients with virus resistant to 2 classes of drug (52 [17%] in the 2/4 -ART arm and 8 [7%] in the C-ART arm; P ϭ .02). The difference between arms was highly significant for resistance to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and marginal for NRTIs and protease inhibitors (PIs), considering the absence of adjustment for multiple comparisons. Table 4 (available only in the electronic version) shows the pattern of resistance mutations by study arm and type of baseline ART regimen. The most frequent mutation was M184V for resistance to NRTIs and K103N for resistance to NNRTIs. Of the 69 patients with virus resistant to NNRTIs, 30 (43%) had virus with 2 NNRTI resistance mutations, and 52 (75%) also had virus resistant to lamivudine (3TC).
Of the 392 patients who were receiving efavirenz at randomization, 386 (98%) had a viral load measurement available at 12 The overall cost of care during the trial was 18% lower in the 2/4 -ART arm than in the C-ART arm, primarily because of differences in antiretroviral drug costs. The rate of lowdensity lipoprotein hypercholesterolemia was significantly different-10 times higher in the C-ART arm. The rate of anemia was 2.8 times higher in the 2/4 -ART arm, with marginal significance (unadjusted P ϭ .04). There was no significant difference for any of the other secondary outcomes.
Withdrawal from the 2/4 -ART strategy. During the study follow-up, 86 patients from the 2/4 -ART arm were prescribed C-ART with no further interruption, yielding an overall rate of withdrawal from the 2/4 -ART strategy of 15.7 withdrawals/100 person-years. Figure 3 shows the probability of withdrawing from the strategy over time. The causes of withdrawal were a decrease in CD4 cell count below 200 cells/ mm 3 (n ϭ 51), pregnancy (n ϭ 13), a severe morbidity event (n ϭ 14), and miscellaneous (n ϭ 8). In multivariate analysis, the only factor associated with the risk of withdrawal was a low CD4 cell count nadir (compared with patients with a CD4 cell count nadir Ͼ250 cells/mm 3 , the hazard ratio of withdrawal was 5.40 for patients with a nadir Ͻ250 cells/mm 3 [95% CI, 2.76 -10.54; P Ͻ .001] and 2.80 for patients with nadir of 200 -250 cells/mm 3 [95% CI, 1.37-5.70; P ϭ .005]). Ancillary analyses. We also stratified the analysis by ART regimen at randomization. We were able to reach the same conclusions for patients who were receiving an NNRTI-based regimen at randomization as for the overall study population. However, no conclusion could be reached with respect to patients who were receiving PIs at randomization, because the sample size was small (table 5, which is available only in the electronic version).
The only factor we found to be independently associated with the risk of resistance to 1 drugs by the end of the trial was CD4 cell count prior to receipt of ART (Ͻ300 cells/mm 3 
DISCUSSION
This report ends the Trivacan trial, launched in 2002. We have previously reported that the CD4 cell count-guided arm of this trial was interrupted prematurely because of excessive morbidity. We report here that the 2/4 -ART arm was noninferior to the continuous strategy in terms of primary outcomes at the end of ϩ 3TC, n ϭ 1) and 52 (68%) with virus resistant to 2 classes (NNRTI ϩ 3TC, n ϭ 48; NNRTI ϩ ZDV ϩ d4T ϩ 3TC, n ϭ 1; 3TC ϩ Ͼ1 PI, n ϭ 3). In the C-ART arm, 10 patients had virus resistant to 1 drug, including 2 patients with virus resistant to 1 drug or 1 class of drug (3TC, n ϭ 1 and Ͼ1 PI, n ϭ 1) and 8 with virus resistant to 2 classes (NNRTI ϩ 3TC, n ϭ 3 and 3TC ϩ Ͼ1 PI, n ϭ 5).
d All morbidity events that led to death and/or hospital admission and that were not documented as severe WHO stage 2-4 events e Other costs, including non-antiretroviral drugs, clinic visits, hospitalizations, and laboratory monitoring, were similar between study arms (data not shown). the trial. Yet, we conclude that this 2/4 -ART strategy should not be recommended, given the Trivacan study design. This is true for 2 reasons. First, although the 2/4 -ART strategy nominally meets the predetermined criteria for noninferiority, the clinical significance of this finding is uncertain because the proportion of subjects in the C-ART study arm who reached the principal primary end point was lower than expected. The study was powered on the proportion of subjects with a CD4 cell count Ͻ350 cells/ mm 3 , assuming that this proportion would be 30% in the control arm. However, only 6% of patients in the C-ART arm had counts Ͻ350 cells/mm 3 by the end of the trial. With such a small proportion in the control arm, it would be clinically questionable to consider the 2/4 -ART arm noninferior to the C-ART arm on the basis of an NIB of Ϫ15%.
Second, on the noninferiority approach, one is willing to accept the uncertain possibility that the new strategy might be slightly inferior to the reference strategy, provided that this uncertainty is balanced by concrete benefits in terms of secondary outcomes. If no secondary benefits are found, there is no reason to replace the reference strategy with the new one, even once it is shown to be noninferior. In our study, the cost of care was lower for the 2/4 -ART group, but resistance to antiretroviral drugs was higher in the 2/4 -ART group. In the long term, drug resistance is likely to increase demand for second-line drugs, thereby increasing cost. Thus, the cost reduction cannot be projected over the long term, as opposed to the increase in drug resistance.
The risk of STI-induced resistance to antiretroviral drugs has been previously reported by others [7, 14, 27-29, 35, 36] , but most randomized STI trials did not report resistance as a major concern [8, 10 -12, 15] . This disparity may have several explanations. First, the risk of resistance is higher for NNRTI-based regimens and the proportion of patients receiving a NNRTI-based ART regimen was particularly high in our trial. Second, in our trial patients remained on dual NRTIs after NNRTI discontinuation for a slightly shorter period of time, compared with previous trials. Third, our patients were all of African origin and were predominantly women, 2 characteristics hypothesized to be associated with NNRTI half-life [30, 33, 34] . Even if the 5-day dual NNRTI covering period was too short, we do not have sufficient data to determine an optimal staggered interruption procedure. Furthermore, there is extensive evidence of wide interpatient variability in NNRTI elimination [30 -32] , making it difficult to determine a standard procedure for all patients. Because of the randomized trial design, to our knowledge our data provide the first accurate estimate of the additional risk of resistance associated with each new interruption of efavirenz in African adults. At 24 months, after 4 cycles of interruptionreintroduction, the difference in resistance to efavirenz between arms was 20% and was about twice as high as the difference at 12 months, after 2 cycles. Thus, the additional risk at each new efavirenz interruption was close to 5%. Interestingly, among the NNRTI-resistant strains, 75% were also resistant to 3TC, and 43% had more than 1 NNRTI-resistance mutation, illustrating the consequences of sustained replication under selective NNRTI pressure. A 5% resistance penalty at each new NNRTI interruption is clearly an unacceptable risk.
These data lead us to propose 3 conclusions. First, previous evidence has shown that CD4 cell count-guided treatments with interruption and reintroduction thresholds at 350 and 250 CD4 cells/mm 3 , respectively, were to be avoided, principally because of morbidity concerns [8, 20] . We now suggest that fixed-cycle episodic treatments with 2 NRTIs plus 1 NNRTI should also be definitively ruled out. Future STI trials should consider restricting STI to patients with high CD4 cell count nadirs who are receiving PI-based regimens.
Second, our results confirm that patients who start an efavirenz-based treatment regimen should be warned about the risk of interrupting efavirenz and NRTIs simultaneously. Although this study provides good evidence for recommending against STI with NNRTIs, the most common reason for abrupt treatment interruptions is drug toxicity. If patients interrupt efavirenz abruptly, they should continue to take the 2 NRTIs and consult their physician as soon as possible for advice on what to do next (i.e., staggered interruption or substitution) [36] .
Third, in sub-Saharan Africa, where NNRTI regimens are recommended as the standard for first-line ART, these data provide strong arguments for warning about the risk created by any potential cause of ART discontinuation that may occur outside the framework of a structured strategy. Factors that may lead to such discontinuation include patient-related factors, such as incomplete adherence, as well as program-related factors, such as depletion of drug stocks [37] . 
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